registry, as of 2026-11-02
https://clinicaltrials.gov/study/NCT06924320
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Pfizer. Enrollment 201. Conditions Obesity and Obesity-related Medical Conditions. This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
ClinicalTrials.gov NCT06924320 protocol and results modules
registry, as of 2026-05-26Stale
https://clinicaltrials.gov/study/NCT07022977
A Study of MET233 in Individuals With Obesity or Overweight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 144. Conditions Obesity and Overweight. The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-weekly subcutaneous injections of MET233 in otherwise healthy adults with overweight or obesity. This study will be conducted in four parts: * Part A will evalu
ClinicalTrials.gov NCT07022977 protocol and results modules
Registry NCT06924320
Phase Phase 1/2
Status Completed
Enrollment 201
Start 2025-03-06
Primary completion 2026-09-29
Study completion 2026-09-29
Catalyst Primary completion. 2026-09-29. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.
Part A Cohort
Regimen every 4 weeks
Weeks 4
Population Obesity and Obesity-related Medical Conditions
Part B Cohort
Regimen every 4 weeks
Weeks 4
Population Obesity and Obesity-related Medical Conditions
Part C Cohort
Regimen every 4 weeks
Weeks 4
Population Obesity and Obesity-related Medical Conditions
Part D Cohort
Regimen every 4 weeks
Weeks 4
Population Obesity and Obesity-related Medical Conditions
Part E Cohort
Regimen every 4 weeks
Weeks 4
Population Obesity and Obesity-related Medical Conditions
Part G Cohort
Regimen every 4 weeks
Weeks 4
Population Obesity and Obesity-related Medical Conditions
Registry NCT07022977
Phase Phase 1
Status Completed
Enrollment 144
Start 2024-11-06
Primary completion 2026-04-21
Study completion 2026-04-21
Catalyst Primary completion. 2026-04-21. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale
(Part A) MET233
Regimen once weekly
Weeks 12
Comparator placebo
Population Obesity and Overweight
(Part A) Placebo
Regimen once weekly
Weeks 12
Population Obesity and Overweight
(Part B) MET233
Regimen weekly
Weeks 12
Comparator placebo
Population Obesity and Overweight
(Part B) Placebo
Regimen weekly
Weeks 12
Population Obesity and Overweight
(Part C) MET233
Regimen once monthly
Weeks 12
Comparator placebo
Population Obesity and Overweight
(Part C) Placebo
Regimen once monthly
Weeks 12
Population Obesity and Overweight
(Part D) MET233
Regimen once monthly
Weeks 12
Comparator placebo
Population Obesity and Overweight
(Part D) Placebo
Regimen once monthly
Weeks 12
Population Obesity and Overweight